Cotrimoxazole is an antibiotic. Pseudomonas aeruginosa has a drug resistant rate of 66% in the years 2010-2013.
World Health Organization (WHO)
The combination of sulfamethoxazole and trimethoprim (5:1) was
introduced in 1971 for the treatment of a wide variety of bacterial infections. Its use
has been associated with severe sensitivity reactions, many of which have been
attributed to the sulphonamide component. Elderly people seem to be more
vulnerable. The World Health Organization has no information further to the above
concerning restrictive action taken on this combination.
Trimethoprim/sulfamethoxazole on a daily basis has a rapid onset of action
but has rare associated side effects of bone marrow suppression and toxic
epidermal necrolysis (TEN).
Nausea, vomiting, and anorexia are generally dose related.
Hypersensitivity reactions (including Stevens-Johnson syndrome and hematologic
reactions) occur in <5% of patients.
One to two tablets a day. Trimethoprim is dosed at 200 mg/24 hours
given either q.d. or b.i.d.
